drugset / Trial / NCT06837129
Intravenous Nalbuphine for Prevention of Intrathecal Morphine-induced Nausea and Vomiting in Patients Undergoing Cesarean Section: A Double-blind, Randomized Controlled Trial.
RandomizedParallel-groupTriple-blindPrevention
Summary
We study efficacy of iv nalbuphine in prevention of intrathecal morphine-induced nausea and vomiting in patients undergoing cesarean section.
Timeline
- Start
- 2023-11-15
- Primary completion
- 2025-02-15
- Completion
- 2025-02-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nalbuphine | Small molecule | 4 mg | Intravenous |
Indications
No indication recorded.